Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CD38 | P28907 | 5/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 3/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769785 | 1.00 | CNR1 (0.47) | CNR1IDO1CNR2CD38MCHR1 | |
| SCHEMBL29769796 | 0.85 | CD38 (0.47) | CNR1CNR2CD38MCHR1KCNH2 | |
| Hydrochloric Acid SCHEMBL29769798 | 0.84 | CD38 (0.46) | CNR1CNR2CD38MCHR1KCNH2 | |
| SCHEMBL29769794 | 0.83 | CD38 (0.49) | CNR1CNR2CD38MCHR1KCNH2 | |
| SCHEMBL24676146 | 0.83 | CD38 (0.49) | CNR1CNR2CD38MCHR1KCNH2 | |
| SCHEMBL24676743 | 0.81 | CD38 (0.47) | CNR1CD38MCHR1KCNH2ADORA1 | |
| SCHEMBL29769775 | 0.81 | CD38 (0.47) | CNR1CD38MCHR1KCNH2ADORA1 | |
| SCHEMBL24677011 | 0.80 | CD38 (0.45) | CNR1CNR2CD38MCHR1KCNH2 | |
| SCHEMBL29769786 | 0.80 | CD38 (0.45) | CNR1CNR2CD38MCHR1KCNH2 | |
| SCHEMBL24676784 | 0.79 | CD38 (0.45) | CNR1CNR2CD38MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279224-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | claimed |
| EP-4284511-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | Boehringer Ingelheim International GmbH (DE) | 2023-12-06 | — | — | EP | claimed |
| EP-4674415-A2 | AZAQUINOLINES AS INHIBITORS OF CD38 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4284511-B1 | AZAQUINOLINES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240279224-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4284511-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | Boehringer Ingelheim International GmbH (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-20220242862-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279224-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | CD38, NQO1, NQO2 | CNR1 806/4885IDO1 1257/4885CNR2 1202/4885 |
| US-20220242862-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | CD38, NQO2, NQO1 | CNR1 1506/4885IDO1 1082/4885CNR2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.